10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELEVANCE HEALTH, INC. | |||
Ticker: ELV Fiscal Year: 2011 | |||
Consolidated Statements Of Cash Flows | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 22, 2012) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Operating activities | |||
| Net income | $ 2,646,700 | 2,887,100 | 4,745,900 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Net realized gains/losses on investments | (235,100) | (194,100) | (56,400) |
| Other-than-temporary impairment losses recognized in income | 93,300 | 39,400 | 450,200 |
| Loss on disposal of assets | 3,300 | 1,900 | 16,400 |
| Gain on sale of business | (3,792,300) | ||
| Deferred income taxes | 74,300 | 101,800 | 61,300 |
| Amortization, net of accretion | 541,500 | 497,700 | 446,400 |
| Impairment of goodwill and other intangible assets | 21,100 | 262,500 | |
| Depreciation expense | 95,700 | 103,100 | 107,100 |
| Impairment of property and equipment | 95,300 | ||
| Share-based compensation | 134,800 | 136,000 | 153,600 |
| Excess tax benefits from share-based compensation | (42,200) | (28,100) | (9,600) |
| Changes in operating assets and liabilities, net of effect of business combinations: | |||
| Receivables, net | (401,800) | 109,700 | (484,200) |
| Other invested assets | (8,900) | 5,100 | (62,500) |
| Other assets | (259,200) | (320,100) | (119,300) |
| Policy liabilities | 978,000 | (330,700) | (748,200) |
| Unearned income | 35,100 | (158,600) | (27,300) |
| Accounts payable and accrued expenses | (208,700) | (58,200) | 952,800 |
| Other liabilities | (13,600) | (208,400) | (248,800) |
| Income taxes | (44,600) | (1,239,800) | 1,391,400 |
| Other, net | (14,200) | (43,500) | (100) |
| Net cash provided by operating activities | 3,374,400 | 1,416,700 | 3,038,900 |
| Investing activities | |||
| Purchases of fixed maturity securities | (11,914,800) | (10,567,200) | (7,186,800) |
| Proceeds from fixed maturity securities: | |||
| Sales | 10,446,200 | 7,215,100 | 4,096,600 |
| Maturities, calls and redemptions | 1,891,300 | 3,321,700 | 1,551,700 |
| Purchases of equity securities | (355,600) | (350,900) | (318,900) |
| Proceeds from sales of equity securities | 287,400 | 197,900 | 577,300 |
| Purchases of other invested assets | (207,900) | (91,400) | (49,000) |
| Proceeds from sales of other invested assets | 29,400 | 34,500 | 3,500 |
| Changes in securities lending collateral | 28,900 | (504,800) | 132,400 |
| Purchases of subsidiaries, net of cash acquired | (600,000) | (300) | (66,300) |
| Proceeds from sales of subsidiaries, net of cash sold | 4,672,300 | ||
| Purchases of property and equipment | (519,500) | (451,400) | (378,400) |
| Proceeds from sales of property and equipment | 3,700 | 800 | 400 |
| Other, net | (31,100) | (75,500) | (32,000) |
| Net cash (used in) provided by investing activities | (942,000) | (1,271,500) | 3,002,800 |
| Financing activities | |||
| Net proceeds from (repayments of) commercial paper borrowings | 463,600 | (164,400) | (397,000) |
| Proceeds from long-term borrowings | 1,097,400 | 1,088,500 | 990,300 |
| Repayments of long-term borrowings | (705,100) | (481,700) | (919,300) |
| Proceeds from short-term borrowings | 100,000 | 100,000 | |
| Repayments of short-term borrowings | (100,000) | (98,000) | |
| Changes in securities lending payable | (29,000) | 504,900 | (132,400) |
| Changes in bank overdrafts | 264,300 | (28,000) | (344,100) |
| Repurchase and retirement of common stock | (3,039,800) | (4,360,300) | (2,638,400) |
| Cash dividends | (357,800) | ||
| Proceeds from issuance of common stock under employee stock plans | 245,000 | 143,600 | 126,500 |
| Excess tax benefits from share-based compensation | 42,200 | 28,100 | 9,600 |
| Net cash used in financing activities | (2,019,200) | (3,169,300) | (3,402,800) |
| Effect of foreign exchange rates on cash and cash equivalents | (400) | (3,200) | (6,700) |
| Change in cash and cash equivalents | 412,800 | (3,027,300) | 2,632,200 |
| Cash and cash equivalents at beginning of year | 1,788,800 | 4,816,100 | |
| Cash and cash equivalents at end of year | 2,201,600 | 1,788,800 | 4,816,100 |
| External Links | |
| ELEVANCE HEALTH, INC. (ELV) Fiscal Year 2011 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |